Keith Thomas Flaherty, M.D.
This page shows the publications co-authored by Keith Flaherty and Raj Kumar.
A novel multi-CDK inhibitor P1446A-05 restricts melanoma growth and produces synergistic effects in combination with MAPK pathway inhibitors. . 2016 07 02; 17(7):778-84.
MITF Modulates Therapeutic Resistance through EGFR Signaling. J Invest Dermatol. 2015 Jul; 135(7):1863-1872.
EPHA2 is a mediator of vemurafenib resistance and a novel therapeutic target in melanoma. Cancer Discov. 2015 Mar; 5(3):274-87.
Vemurafenib synergizes with nutlin-3 to deplete survivin and suppresses melanoma viability and tumor growth. Clin Cancer Res. 2013 Aug 15; 19(16):4383-91.
The connection strength for co-authors is the sum of the scores for each of their shared publications.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.